Journal
CANCER LETTERS
Volume 501, Issue -, Pages 247-262Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.11.002
Keywords
Arginine methylation; Liver cancer; Protein arginine methyltransferase 6; Sorafenib; Hypoxia; Nutrient deprivation
Categories
Funding
- Centre for Comparative Medicine Research (University of Hong Kong)
- Research Grants Council of Hong Kong - General Research Fund [17143516, 17105917]
- Research Grants Council of Hong Kong - Collaborative Research Fund [C7026-18G]
Ask authors/readers for more resources
Autophagy plays a critical role in cancer cells such as hepatocellular carcinoma (HCC), and deficiency of the post-translational modification enzyme PRMT6 promotes autophagy induction in HCC under stress conditions. PRMT6 interacts with and methylates BAG5 to regulate HSC70 stability, influencing autophagy in HCC cells. Targeting BAG5 may be a promising strategy in HCC treatment to suppress autophagy and enhance sensitivity to sorafenib.
Autophagy is a critical survival factor for cancer cells, whereby it maintains cellular homeostasis by degrading damaged organelles and unwanted proteins and supports cellular biosynthesis in response to stress. Cancer cells, including hepatocellular carcinoma (HCC), are often situated in a hypoxic, nutrient-deprived and stressful microenvironment where tumor cells are yet still able to adapt and survive. However, the mechanism underlying this adaptation and survival is not well-defined. We report deficiency of the post-translational modification enzyme protein arginine N-methyltransferase 6 (PRMT6) in HCC to promote the induction of autophagy under oxygen/nutrient-derived and sorafenib drug-induced stress conditions. Enhanced autophagic flux in HCC cells negatively correlated with PRMT6 expression, with the catalytic domain of PRMT6 critically important in mediating these autophagic activities. Mechanistically, PRMT6 physically interacts and methylates BAG5 to enhance the degradation of its interacting partner HSC70, a well-known autophagy player. The therapeutic potential of targeting BAG5 using genetic approach to reverse tumorigenicity and sorafenib resistance mediated by PRMT6 deficiency in HCC is also demonstrated in an in vivo model. The clinical implications of these findings are highlighted by the inverse correlative expressions of PRMT6 and HSC70 in HCC tissues. Collectively, deficiency of PRMT6 induces autophagy to promote tumorigenicity and cell survival in hostile microenvironments of HCC tumors by regulating BAG5-associated HSC70 stability through post-translational methylation of BAG5. Targeting BAG5 may therefore be an attractive strategy in HCC treatment by suppressing autophagy and inducing HCC cell sensitivity to sorafenib for treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available